ULTRAGENYX PHARMACEUTICAL INC. Stock Split Ratio
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Stock Split Ratio of 31.90% for the 1-month period ending 2014-01-17, per its 10-Q filed 2014-08-11.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2015-03-27
- 2014-01-17: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 313.45%; Stockholders' Equity Note, Stock Split, Conversion Ratio 31.90%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 31.90%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed 313.45%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed |
|---|---|---|---|---|
| 2014-01-17 | 313.45% 10-K · filed 2015-03-27 | 31.90% 10-Q · filed 2014-11-10 | 31.90% 10-Q · filed 2014-08-11 | 313.45% 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |